Recon: FDA grants priority review for traditional approval of Biogen, Eisai’s Leqembi; Merck drug shows promise in pulmonary hypertension
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy